China-Japan Friendship Hospital

TUESDAY, July 9, 2024 -- Prediabetes can be successfully fought through diet and exercise, a new study shows. People with prediabetes can reduce their long-term risk of death and illness if they use diet and exercise to delay the onset of diabetes for just four years, according to findings published July 9 in the journal PLOS Medicine . Prediabetes -- also known as impaired glucose tolerance (IGT) -- involves blood sugar levels that are higher than normal, but haven’t reached the levels associated with full-blown diabetes. “This study suggests that a longer duration of non-diabetes status in those with IGT has beneficial health outcomes" and reduces premature death, concluded the research team led by Dr. Guangwei Li of the China-Japan Friendship Hospital in Da Qing City, China. For the study, researchers tracked the health of 540 people with prediabetes who participated in an earlier six-year clinical trial. In the trial, prediabetic people were assigned to one of four groups – one that followed a healthy diet; one that got more exercise; one that both ate well and exercised; and a control group. After more than 30 years of follow-up, researchers found that people who didn’t lapse into diabetes for at least four years after their diagnosis with prediabetes had a significantly lower risk of dying or experiencing a heart health event like a heart attack or stroke. That protective effect was not found in people who became full-fledged diabetic within less than four years, researchers said. The results suggest that the longer a prediabetic person delays the onset of diabetes, the better their long-term health will be, researchers concluded. “The implementation of effective interventions targeting those with IGT should be considered as part of preventative management for diabetes and diabetes related vascular complications,” the team wrote. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

ROCKVILLE, Md.and SUZHOU,China, Nov. 21, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that full results from a Phase 2 clinical trial of mazdutide (Innovent R&D code: IBI362), a glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, in Chinese patients with type 2 diabetes (T2D) were published in Diabetes Care. Professor Wenying Yang, the corresponding author, principal investigator of the study from China-Japan Friendship Hospital, stated, "The rate of achieving target blood glucose control in Chinese patients with T2D is still low. T2D is often accompanied by a variety of cardiometabolic risk factors, such as obesity, hyperlipidemia, coronary heart disease, fatty liver, and gout. Those comorbidities not only increase the disease burden, but also add to the difficulty and complexity of treatment. There is an urgent clinical need for safe, efficacious and innovative medicines to treat diabetes that offer improved patient convenience, weight loss effect, multiple cardiometabolic benefits and low hypoglycemic risk. The Phase 2 full results of mazdutide, published in Diabetes Care, not only demonstrated its robust efficacy in glycemic control but also the advantage to reduce HbA1c and body weight at the same time in Chinese patients with T2D, suggesting additional benefits to diabetes patients living with obesity. This 20-week phase 2 study also shows multiple cardiometabolic benefits and favorable safety profile brought by mazdutide treatment. I look forward to more encouraging results from two ongoing Phase 3 studies of mazdutide in Chinese patients with T2D, potentially bringing this novel treatment option to patients as soon as possible." Dr. Lei Qian, Vice President of Clinical Development of Innovent, stated, "The publication in a top-tier medical journal in the field of diabetes is another important achievement for mazdutide as potential first-in-class GLP-1R/GCGR dual agonist. This Phase 2 study in Chinese patients with T2D demonstrated mazdutide's differentiated advantage as a dual agonist that not only lowers glucose, but also controls weight and brings multiple cardiometabolic benefits for T2D patients. Furthermore, the consistently favorable safety profile further validates the good safety and tolerability of this novel molecule as observed in accumulated studies. Notably, we compared the efficacy of mazdutide with dulaglutide in this phase 2 study, and obtained encouraging results, reinforcing our confidence in mazdutide's potential. The registrational Phase 3 studies of mazdutide in Chinese T2D patients (DREAMS-1 and DREAMS-2) are currently underway, and will provide further critical clinical evidence in Chinese T2D patients. We hope that this high-quality medicine will benefit Chinese patients living with T2D as soon as possible. " In this randomized, double-blind, placebo-controlled Phase 2 trial (ClinicalTrials.gov, NCT04965506), a total of 252 patients with T2D inadequately controlled with diet and exercise alone or with stable metformin (glycated hemoglobin A1c [HbA1c] 7.0–10.5%) were randomly assigned to receive 3 mg mazdutide, 4.5 mg mazdutide, 6 mg mazdutide, 1.5 mg open-label dulaglutide, or placebo subcutaneously for 20 weeks. The primary outcome was change in HbA1c from baseline to week 20. The mean BMI baseline was 27.4 kg/m2 and mean HbA1c baseline was 8.06% for participants who received at least one dose of study treatment (n=250). All doses of mazdutide significantly reduced HbA1c levels compared with placebo. The mean change from baseline to week 20 in HbA1c levels were −1.41% with mazdutide 3 mg, −1.67% with mazdutide 4.5 mg, and −1.55% with mazdutide 6 mg (−1.35% with dulaglutide and 0.03% with placebo). The reductions in HbA1c were significantly greater with mazdutide compared with placebo (all P<0.0001). Meanwhile, the proportion of patients with HbA1c ＜7.0% at week 20 were 54.0%, 66.7% and 73.5% with mazdutide 3 mg, 4.5 mg and 6 mg, respectively (60.0% with dulaglutide and 17.6% with placebo); The proportion of patients with HbA1c ≤6.5% at week 20 were 28.0%, 56.3% and 51.0% with mazdutide 3 mg, 4.5 mg and 6 mg, respectively (46.0% with dulaglutide and 7.8% with placebo). Furthermore, mazdutide also significantly reduced fasting plasma glucose and 2-hour postprandial glucose. All doses of mazdutide significantly reduced body weight along with HbA1c target. The mean percent change from baseline to week 20 in body weight were −4.12%, −5.31%, and −7.11% with mazdutide 3 mg, 4.5 mg and 6 mg, respectively (−2.69% with dulaglutide and −1.38% with placebo). Meanwhile, the proportion of patients with body weight loss of ≥5% at week 20 were 24.0%, 37.5% and 57.1% with mazdutide 3 mg, 4.5 mg and 6 mg, respectively (18.0% with dulaglutide and 9.8% with placebo); At week 20, 16.0% with mazdutide 3 mg, 29.2% with mazdutide 4.5 mg and 49.0% with mazdutide 6 mg achieved body weight loss of ≥5% and HbA1c of <7.0% (12.0% with dulaglutide and 0 with placebo). Mazdutide was safe and well-tolerated. No patient discontinued study drug due to adverse events. No investigator-judged study drug-related serious adverse event occurred. No severe hypoglycemia events occurred. The overall safety profile of mazdutide was similar to those observed in previous studies of mazdutide and other GLP-1-based drugs. The most frequently reported treatment-emergent adverse events included diarrhea, decreased appetite, nausea and vomiting, most of mild or moderate severity. At week 20, the mean increase in heart rate from baseline in mazdutide groups was comparable to that of the dulaglutide group. No signal of increased cardiovascular risk was observed. Furthermore, mazdutide also reduced waist circumference, blood pressure, low-density lipoprotein cholesterol and triglycerides, and improved insulin sensitivity, providing comprehensive benefits to patients with T2D. Full results can be found in the Diabetes Care. About Diabetes The prevalence of diabetes among adults in China is 11.6%, of which type 2 diabetes accounts for about 90% of the total number of diabetic patients, and the number of patients is still increasing. Poor glycemic control will lead to irreversible microvascular and macrovascular complications such as decreased visual acuity, blindness, renal insufficiency, peripheral neuropathy, myocardial infarction, stroke, amputation, etc. As a latent disease with serious complications and high incidence, diabetes mellitus has seriously threatened human health. Currently, there are many treatment options for diabetes, and in addition to effective glycemic control, the development of new hypoglycemic drugs may also provide additional benefits for diabetic patients in terms of weight loss, cardiovascular risk reduction, and renal protection. About Mazdutide (IBI362) Innovent entered into a licensing agreement with Eli Lilly and Company (Lilly) for the development and potential commercialization of OXM3 (also known as mazdutide), a GLP-1R and GCGR dual agonist, in China. As a mammalian oxyntomodulin (OXM) analogue, in addition to the effects of GLP-1 receptor agonists on promoting insulin secretion, lowering blood glucose and reducing body weight, mazdutide may also increase energy expenditure and improve hepatic fat metabolism through the activation of glucagon receptor. Mazdutide has demonstrated excellent weight loss and glucose-lowering effects in clinical studies, as well as reducing waist circumference, blood lipids, blood pressure, blood uric acid, liver enzymes and liver fat content, as well as improving insulin sensitivity, bringing multiple metabolic benefits. Currently, three key phase 3 studies of mazdutide 4 mg and 6 mg in Chinese patients with overweight or obesity (GLORY-1) and type 2 diabetic (DREAMS1 and DREAMS-2) subjects are underway. The Phase 2 clinical study of mazdutide 9 mg in Chinese patients with obesity is in progress. The Phase 3 clinical study of mazdutide 9 mg in Chinese subjects with obesity will be start at the end of 2023. About Innovent Inspired by the spirit of "Start with Integrity, Succeed through Action," Innovent's mission is to discover and develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people. Established in 2011, Innovent is committed to discovering and developing, manufacturing and commercializing high-quality innovative medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, and ophthalmology diseases to enhance the quality of the patients' lives. Innovent has 10 products in the market, including TYVYT® (Sintilimab Injection), BYVASDA® (Bevacizumab Injection), SULINNO® (Adalimumab Injection), HALPRYZA® (Rituximab Injection), Pemazyre® (Pemigatinib Oral Inhibitor), olverembatinib, Cyramza® (Ramucirumab Injection), Retsevmo® (Selpercatinib Capsules), FUCASO® (Equecabtagene Autoleucel Injection) and SINTBILO® (Tafolecimab Injection). Additionally, 7 assets are in Phase III or pivotal clinical trials, and 17 more molecules are in early clinical stage. Innovent has also entered into 30 strategic collaborations with Eli Lilly, Roche, Sanofi, Adimab, Incyte, MD Anderson Cancer Center and other international partners. We strive to work with many collaborators to help advance the biopharmaceutical industry, improve drug availability and enhance the quality of the patients' lives. For more information, please visit: . and Disclaimer: Innovent does not recommend any off-label usage. Forward-looking statement This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics ("Innovent"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions. The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect. SOURCE Innovent Biologics

BEIJING, March 24, 2023 /PRNewswire/ -- China has entered a new phase of epidemic prevention and control after it downgraded the management of COVID-19 response into Class B infectious diseases. "The overall situation of epidemic response is good nationwide," according to a meeting held by the Standing Committee of the Political Bureau of the Communist Party of China Central Committee on February 16. Current situation of COVID-19 in China Seen from the latest data released by the Chinese Center for Disease Control and Prevention (China CDC), the number of positive nucleic acid tests in China has been basically at a downward trend as of March 16, dropping below 8,000 cases for over a week. Infections from the epidemic are still occurring in China at a localized and sporadic level, Wu Zunyou, chief epidemiologist at the China CDC, said at an interview in early March. No one can tell how COVID-19 will eventually play out, said Wu, adding that the novel coronavirus will coexist with humans on Earth for a long time. Zhan Qingyuan, deputy director at the Department of Pulmonary and Critical Care Medicine of the China-Japan Friendship Hospital (CJFH), reiterated the same to CGTN: "People may have to live with the microorganism, as we can't kill all the coronavirus." As the COVID-19 epidemic has "basically ended" in the country, the hospital has been operating at pre-epidemic level amid a surge of seasonal influenza, of which the positive rate of influenza virus has increased to 53.2 percent in the week from March 6 to 12, far above the data in early February – lower than 1 percent, according to statistics from the China CDC. Zhan advised the elderly and those with underlying conditions to get vaccinated, and to keep handy a thermometer, antigen reagents and COVID-19 drugs. "I recommend taking medicine once the nucleic acid test is positive, because the earlier the drugs against COVID-19 is used, the better the effect is." Preparations still being made for COVID-19 Everything in China is back to normal, while key institutions like the hospitals are still getting prepared. Amid seasonal influenza, Zhong Lintao, director at the Nosocomial Infections Management Office of the CJFH, said that doctors at the hospital's fever clinic have triaged patients based on the severity of their condition, instead of results of nucleic acid tests in the past three years. In addition, the hospital is also dedicated to daily infection prevention and control, according to Zhong, "For example, we provide guidance on personal protection for medical staff and patients, clean and disinfect frequently touched items on a daily basis to prevent the spread of the virus in medical institutions." Zhong said they have accumulated much experience in the last round of the COVID-19 epidemic and can transform from normal operations to rapid response to a disease outbreak, including allocating medical personnel to the fever clinic, emergency department and wards, and storing medicines and medical devices. "We will also expand the capacity of the emergency department by transforming specialist wards in other departments to treat severe cases once there is a need," said Zhong. The hospital converted a building into wards to care for critically-ill COVID-19 patients last December, and although normal service has resumed, Zhong said they can convert it into wards again quickly if needed. Strengthening weak links China's National Development and Reform Commission (NDRC), National Health Commission and six other departments have issued a notice and deployed relative work on consolidating major achievements of epidemic prevention and control, and strengthening the weak links in urban and rural medical and health care and environmental protection, said Liu Dechun, director at the NDRC's Department of Resource Conservation and Environmental Protection, at a media conference last Thursday. According to Liu, China will strengthen the capacity of epidemic surveillance and regular early warning and response systems, and improve health monitoring facilities and capacity in key institutions such as medical and elderly care institutions, and large shopping malls. It also urged to coordinate and allocate medical supplies and resources, and to build a tiered, multi-level, and referral-based healthcare system in a regular manner and build three-tiered healthcare networks –the primary, secondary and tertiary hospitals – with public medical institutions as the mainstay, according to Liu. Liu said that the country will improve sanitation facilities in crowded places and carry out environmental health governance in places like urban villages and farmers' markets. SOURCE CGTN